SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalAvadel AVDL


Previous 10 Next 10 
From: Arthur Radley9/22/2009 10:45:22 AM
   of 240
 
cc.talkpoint.com

Would suggest all listen to the UBS presentation this morning. The project announced for the funding being done by the French government is important..........listen to Willard's explanation, plus the 'promised' two new projects this Q and next Q.

One has to appreciate Willard's constant reminder of the 'shareholders' in the company plans. Sort of novel to have a CEO being concerned about the investors. (:>)

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Arthur Radley who wrote (218)11/4/2009 8:47:38 AM
From: Arthur Radley
   of 240
 
Flamel Technologies Announces Licensing Agreement with Pfizer
8:00 am ET 11/04/2009 - Business Wire
LYON, France--(BUSINESS WIRE)--

Flamel Technologies (Nasdaq:FLML) today announced that Pfizer (NYSE:PFE)

has exercised its option to license Flamel's Medusa(R) technology for the

development of a controlled release formulation of an already-marketed

therapeutic protein. Flamel will receive a further payment of $1 million

pursuant to the exercise of the license; Pfizer will pay all development

costs of the program, including milestone payments and royalties on any

worldwide commercial sales. The program was begun in 2007 with Wyeth,

which was acquired by Pfizer last month. The program leverages Flamel's

ability to create controlled-release formulations of therapeutic

proteins for intravenous administration.

Stephen H. Willard, Flamel's chief executive officer, commented,

"Pfizer's decision to move forward follows a two year evaluation period

during which Flamel has developed and demonstrated an aspect of the

Medusa platform which allows us to work on controlled release

formulations of molecules that are injected intravenously. We believe

that this work has the potential to benefit patients in many ways, not

least by lessening the time and costs associated with frequent hospital

visits."

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Arthur Radley who wrote (219)11/4/2009 1:31:17 PM
From: Arthur Radley
   of 240
 
Q report is now on schedule for Friday of this week. The key will be whether they can continue to build their cash position. From the 1Q to the 2Q they increased cash from $39.1 million to $45.0 Million, so with several previously announced deals being booked during the 3rdQ it will be important to see if they can continue to keep cost down and build their cash reserves. Stock has bounced with PFE deal announcement today, but volume is only average........so appears new money coming in will be keyed to Q report.

Share RecommendKeepReplyMark as Last Read


From: Arthur Radley11/24/2009 5:17:37 PM
   of 240
 
fool.com

Why I still think FLML has a future.......maybe one day!

Share RecommendKeepReplyMark as Last Read


From: Arthur Radley11/28/2009 9:50:50 PM
   of 240
 
online.barrons.com

Share RecommendKeepReplyMark as Last Read


From: Arthur Radley12/18/2009 11:51:30 AM
   of 240
 
New trial for the Medusa program.......and stock is basically dead in the water....(:<)

finance.yahoo.com

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Arthur Radley who wrote (223)12/18/2009 12:01:16 PM
From: rkrw
   of 240
 
Maybe i'll be proven wrong but off hand i don't think the world needs another interferon for hcv at least one that isn't particularly differentiated. Seems like a poor use of their resources.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: rkrw who wrote (224)12/18/2009 12:18:33 PM
From: Arthur Radley
   of 240
 
My guess is that they figured this would be the quickest venue to get another drug approved.......guess they didn't remember the result of Coreg and the huge market they garnered for that one. Appears that FLML and ELN are both working on this method of drug delivery......leaving me to question why I still own shares in these two. I still believe that reformulation for existing drugs will eventually be successful.....but when???? (:<)

Share RecommendKeepReplyMark as Last Read


From: Arthur Radley1/20/2010 4:18:44 PM
   of 240
 
In this horrible market today, FLML swam against the tide...not great volume, but any stock going against the downward bias today........is impressive.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Arthur Radley who wrote (226)3/20/2010 3:16:40 PM
From: Arthur Radley
   of 240
 
quicktake.morningstar.com

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10